XBiotech (XBIT): Clinical-Stage True Human Antibody Developer
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company specializing in True Human monoclonal antibodies. Pipeline candidates include Natrunix and Hutrukin. The company is held by small-cap value ETFs.
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company headquartered in Austin, Texas, that specializes in discovering and developing "True Human" monoclonal antibodies derived from individuals with natural immunity to specific diseases. The company focuses exclusively on antibodies that already exist in the human body, rather than animal-derived or humanized antibodies, and is advancing candidates for cancer, inflammatory conditions, and infectious diseases.
Founded in 2005, the company completed its initial public offering on the NASDAQ in 2015. It operates from a 48-acre campus in Austin, Texas, which houses its manufacturing facilities and research laboratories. Key leadership includes the founder and CEO and the Chief Scientific Officer. Insiders have historically held approximately 36% of the company's shares, a level often viewed as a sign of management's long-term confidence.
XBiotech's pipeline includes Natrunix, a therapy targeting IL-1α currently being evaluated for rheumatoid arthritis and pancreatic cancer, and Hutrukin, an antibody studied for its potential to reduce tissue damage in patients who have suffered a stroke. Revenue is generally derived from licensing agreements or asset sales rather than commercial product sales, and the company has historically maintained a strong cash position.
In 2021, XBiotech distributed a substantial special dividend to shareholders following a major asset sale, and it has engaged in tender offers for share repurchases. As of late 2023 and early 2024, the stock has reflected the typical volatility of the biotech sector, with its 52-week price range reacting sharply to news regarding FDA milestones or partnership deals.
The company is held by several small-cap value ETFs, including the Bridgeway Omni Small-Cap Value ETF, which holds $136.96K in XBiotech stock with a 0.01% weight and a 0.45% expense ratio, and the Avantis U.S. Small Cap Value ETF, which holds $11.2K with a 0.00% weight and a 0.25% expense ratio.